B. Metzler seel. Sohn & Co. Holding AG Acquires New Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,744 shares of the company’s stock, valued at approximately $1,059,000.

A number of other large investors have also modified their holdings of the business. Pathstone Holdings LLC grew its position in shares of TransMedics Group by 4.9% in the third quarter. Pathstone Holdings LLC now owns 26,381 shares of the company’s stock valued at $4,142,000 after purchasing an additional 1,231 shares in the last quarter. Thrivent Financial for Lutherans acquired a new position in TransMedics Group during the third quarter worth $4,113,000. Mutual of America Capital Management LLC purchased a new stake in TransMedics Group in the 3rd quarter valued at $784,000. Vaughan Nelson Investment Management L.P. increased its stake in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after acquiring an additional 64,360 shares during the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of TransMedics Group by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 78,073 shares of the company’s stock worth $12,258,000 after acquiring an additional 17,933 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on TMDX shares. Needham & Company LLC restated a “hold” rating and set a $109.00 price objective on shares of TransMedics Group in a research report on Friday. TD Cowen cut their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Piper Sandler decreased their price objective on TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a report on Wednesday. Oppenheimer cut their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Finally, Baird R W raised TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Stock Down 4.2 %

Shares of TMDX opened at $76.04 on Friday. The company’s 50-day simple moving average is $119.18 and its 200-day simple moving average is $137.70. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 1 year low of $67.77 and a 1 year high of $177.37. The stock has a market capitalization of $2.55 billion, a PE ratio of 80.89 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. The business’s quarterly revenue was up 63.7% on a year-over-year basis. Analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares in the company, valued at $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,958 shares of company stock worth $5,230,528 in the last quarter. 7.00% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.